CXL-1020, a nitroxyl (HNO) prodrug, enhances cardiac inotropy/lusitropy and Ca 2+ cycling in rats exhibiting abnormal relaxation, induces vasorelaxation, and augments cardiac function in canine models. It has been investigated for its potential in treating systolic and stable heart failure [1].

CXL-1020, administered at a dosage of 100 μg/kg/min via a 30-minute infusion, significantly improves hemodynamics and cardiac functionality, enhancing both diastolic and systolic performance in mice [1]. Conversely, at dosages of 3 and 10 mg/kg/min through a 4-hour intravenous infusion, CXL-1020 elevates left ventricular systolic and diastolic functions in dogs suffering from advanced heart failure [2]. In an animal model using adult male Sprague-Dawley rats (250-350 g; with cardiac dysfunction induced by isoproterenol) [1], the administration of CXL-1020 at 100 μg/kg/min for 30 minutes noticeably improved hemodynamics and cardiac function in normal rats, and substantially boosted both diastolic and systolic performance in cardiac dysfunction mice. Similarly, in dogs with heart failure induced by coronary microembolization [2], dosages of 3 and 10 mg/kg/min resulted in a dose-dependent improvement in cardiac function, evidenced by a modest decrease in systolic aortic pressure (AoP), a significant increase in ejection fraction (EF) and early mitral inflow velocity deceleration time (DT), and a significant reduction in left ventricular end-systolic volume (ESV), end-diastolic pressure (EDP), and end-diastolic wall stress (EDWS).